Rotavirus Vaccine Cuts Deaths From Rotavirus-Positive Gastroenteritis by Nearly 76% in Global Study

A multinational analysis of more than 27,000 children found that receiving at least 1 dose of a rotavirus vaccine reduced the risk of death from rotavirus-positive acute gastroenteritis by approximately 75.8% (95% CI, 28.4-91.8). Despite this finding, the vaccine's effect against all-cause acute gastroenteritis mortality was smaller and not considered statistically significant, at about 20.8% (95% CI, –47.0 to 57.3).¹

The results, which were published in Lancet Child & Adolescent Health, draw on the Multi-National Subpopulations Study to Evaluate Rotavirus Vaccines (MNSSTER-V), which pooled test-negative case-control data from 24 countries collected between July 2007 and August 2023.¹

Investigators, led by Mary C. Moran, PhD, MPH, of the CDC's Division of Viral Diseases, included 27,252 children younger than 5 years who sought hospital or emergency department care for acute gastroenteritis across 22 countries. Sixteen of those countries reported at least 1 in-hospital death, contributing a combined 183 all-cause acute gastroenteritis deaths and 25 rotavirus-positive deaths to the analysis. Compared with unvaccinated children, those who received at least 1 rotavirus vaccine dose were nearly 14 times less likely to die of acute gastroenteritis (OR, 13.94; 95% CI, 7.21-26.94).^1,2

Rural and Low-Vaccination Children Faced Disproportionate Risk

The study also identified disparities tied to geography and vaccination status. Twelve of the 16 countries reporting deaths were in Africa, and children treated at rural hospitals were nearly twice as likely to have received no rotavirus vaccine doses compared with those in urban settings (10% vs 5.8%). Among children who died with confirmed rotavirus infection, a larger share had received no rehydration therapy and no vaccine doses compared with children who died from other causes of gastroenteritis.²

Investigators Point to Timely Vaccination and Broader Health Infrastructure

Moran and coauthors noted that because younger infants generally face the highest risk of dying from rotavirus and acute gastroenteritis, the findings reinforce the importance of on-schedule vaccination in all settings and that higher coverage could offer indirect protection to children with chronic conditions who face elevated diarrhea mortality risk.¹

In an accompanying study, Daniel Hungerford, PhD; and Latif Ndeketa, PhD, MBBS, both of the University of Liverpool, called the findings the strongest multicountry evidence to date that rotavirus vaccines substantially reduce rotavirus-associated diarrhea mortality in high-burden settings.³

The study authors also flagged an open question raised by prior research: Rotavirus vaccine effectiveness against severe disease is known to decline in the second year of life in low- and middle-income countries, a pattern not seen in wealthier nations; however, it remains unclear whether protection against death follows the same trajectory. Hungerford and Ndeketa argued that closing that gap will require pairing vaccination with birth-dose strategies, injectable alternatives to oral vaccines, and sustained investment in nutrition, sanitation, and health system infrastructure.^2,3

New Federal Policy Shifts Rotavirus Vaccine Off Universal Recommendation

The publication lands amid a notable shift in US vaccine policy. An executive order signed by President Donald J. Trump in August 2026 moves rotavirus vaccination—along with hepatitis A virus, hepatitis B virus, meningococcal disease, influenza virus, and COVID-19 vaccines—from a universal childhood recommendation to a “shared clinical decision-making” category, leaving initiation and timing to conversations between families and clinicians rather than routine default administration.⁴

The order narrows the list of vaccines recommended for all children from 17 to 11 and directs the Department of Health and Human Services to formalize the revised schedule within 90 days. Critics of the policy change have warned that reclassifying rotavirus vaccination could reduce coverage and, by extension, increase hospitalizations and deaths from a virus that still accounts for an estimated 25% of diarrhea deaths among children younger than 5 years worldwide, despite more than 140 countries having included the vaccine in routine immunization programs.⁴

What This Means for Pharmacists

For pharmacists involved in immunization counseling, the MNSSTER-V findings offer a concrete, mortality-based rationale to support timely rotavirus vaccination—particularly relevant as US policy moves toward a shared decision-making framework that places more responsibility on point-of-care conversations. Pharmacists in community and hospital settings may be well positioned to reinforce completion of the full rotavirus series, especially among infants and families in under-resourced or rural settings, where the study found vaccination gaps and mortality risk were highest.^1,2

Expert Insights

To provide additional context on the findings from the MNSSTER-V dataset study, Pharmacy Times spoke with a spokesperson from the CDC about the real-world implications of these results, including how clinicians should interpret the gap between rotavirus-specific and all-cause mortality outcomes, potential sources of heterogeneity across the study's multi-country design, and what pharmacists can do to support vaccine series completion among hesitant caregivers.

Pharmacy Times: Vaccine effectiveness was strong against rotavirus-positive deaths (75.8%) but much weaker and non-significant against all-cause gastroenteritis deaths (20.8%). Is that gap mainly a power issue given only 25 rotavirus-positive deaths, or does it point to other pathogens driving fatal cases?

CDC Spokesperson: Rotavirus vaccines are specific to rotavirus and do not protect against other causes of acute gastroenteritis, so it is not surprising that vaccine effectiveness was lower against all-cause acute gastroenteritis deaths. Rotavirus is the leading cause of pediatric diarrhea deaths and is estimated to be the cause of 25% of pediatric diarrhea deaths in low- and middle-income countries. In our dataset, about 15% of children who died in the hospital tested positive for rotavirus, with the remaining deaths being either rotavirus-negative or missing a rotavirus test result.

Pharmacy Times: Data span 24 countries and 16 years, with mortality outcomes from just 16 countries. How much heterogeneity might that timeframe and setting variation introduce into the pooled estimates?

CDC Spokesperson: The study included data collected over 16 years from 24 countries, reflecting a range of when countries introduced rotavirus vaccines into their national immunization programs and a range of geographic and epidemiologic settings. That variation is an important consideration when interpreting pooled estimates. The analyses accounted for differences in national under-5 mortality strata and child age, and the underlying studies used similar methodologies based on a standard WHO protocol.

By limiting our mortality analyses to the 16 countries that reported a death, we ensured that we were analyzing data from surveillance systems that were sensitive enough to detect deaths occurring in the hospital. Rotavirus vaccines have been shown to be more effective against rotavirus hospitalizations in higher-income countries with low overall under-5 mortality levels. The countries reporting deaths in our dataset were all from countries with high under-5 mortality. These findings are reassuring and suggest that rotavirus vaccines are highly effective at protecting against rotavirus deaths in the settings where most deaths occur.

Pharmacy Times: What's the key message you'd want pharmacists to give hesitant caregivers about completing the full rotavirus vaccine series, given these mortality findings?

CDC Spokesperson: The key message for hesitant caregivers is that rotavirus vaccination can save lives, and completing the recommended vaccine series provides important protection against severe disease. In this study, receiving at least one dose of rotavirus vaccine was associated with 75.8% effectiveness against death from rotavirus-positive acute gastroenteritis.

Pharmacists and other health care professionals can play an important role by having educational and empathetic conversations with caregivers to answer questions, address concerns, and reinforce the importance of completing the recommended vaccine series. Helping families understand the benefits of timely rotavirus vaccination can protect young children from severe illness and reduce preventable rotavirus-related deaths.

REFERENCES

1. Moran MC, Burnett E, Groome MJ, et al; Multi-National Subpopulations Study to Evaluate Rotavirus Vaccines (MNSSTER-V) project working group. Rotavirus vaccine effectiveness against rotavirus and acute gastroenteritis mortality: an analysis of pooled case–control studies from the MNSSTER-V dataset. Lancet Child Adolesc Health. Published online August 12, 2026. doi:10.1016/S2352-4642(26)00158-6

2. Rudd T. Vaccine prevents acute gastroenteritis deaths in cases caused by rotavirus. MedPage Today. August 17, 2026. Accessed August 19, 2026. https://www.medpagetoday.com/pediatrics/vaccines/122639

3. Hungerford D, Ndeketa L. Rotavirus vaccine success and the challenge of vaccine equity. Lancet Child Adolesc Health. Published online August 12, 2026. doi:10.1016/S2352-4642(26)00215-4

4. Delivering gold standard childhood vaccine recommendations for Americans. The White House. August 10, 2026. Accessed August 19, 2026. https://www.whitehouse.gov/presidential-actions/2026/08/delivering-gold-standard-childhood-vaccine-recommendations-for-americans/